Impact of the pneumococcal conjugate vaccine in the management of highly febrile children aged 6 to 24 months in an emergency department

Pediatric Emergency Care

Volumn 22, Issue 8, 2006, Pages 566-569

  Mintegi, Santiago ^a,b   Benito, Javier ^a   González, Maria ^a   Astobiza, Eider ^a   Sanchez, Jesus ^a   Santiago, Mikel ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Fever; Pneumococcus

Indexed keywords

CEFTRIAXONE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; BODY TEMPERATURE; CONTROLLED STUDY; EMERGENCY WARD; FEVER; HUMAN; INFANT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY;

EMERGENCY SERVICE, HOSPITAL; EMERGENCY TREATMENT; FEMALE; FEVER; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VACCINES, CONJUGATE;

EID: 33747506920     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pec.0000230550.79046.68     Document Type: Article

References (23)

1. Mintegi S, Benito J, García S, et al. Patient demand and management in a hospital pediatric emergency setting. An Pediatr (Barc). 2004;61:156-161.
2. Kuppermann N. The evaluation of young febrile children for occult bacteremia: time to reevaluate our approach? Arch Pediatr Adolesc Med. 2002;156:855-857.
3. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med. 1993;22(7):1198-1210.
4. Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med. 1998;152(7):624-628.
5. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am. 1999;46(6):1073-1109.
6. Shapiro ED, Aaron NH, Wald ER, et al. Risk factors for development of bacterial meningitis among children with occult bacteremia. J Pediatr. 1986;109:15-19.
7. Harper MB, Bachur R, Fleisher GR. Effect of antibiotic therapy on the outcome of outpatients with unsuspected bacteremia. Pediatr Infect Dis J. 1995;14(9):760-767.
8. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
9. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 Pt 1):443-449.
10. Whitney CG, Farley MM, Hadler J, et al, Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746.
11. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med. 2004;158(7):671-675.
12. Baraff LJ. Editorial: Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med. 2003;42(4):546-549.
13. Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000;36(6):602-614.
14. Nigrovic LE, Malley R. Evaluation of the febrile child 3 to 36 months old in the era of pneumococcal conjugate vaccine: focus on occult bacteremia. Clin Ped Emerg Med. 2004;5:13-19.
15. Mintegi S, González M, Pérez A, et al. Infants aged 3-24 months with fever without source in the emergency room: characteristics, management and outcome. An Pediatr. 2005;62(6):522-528.
16. Klein JO. Management of pediatric pneumococcal diseases in the era of the pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2002;21:582-584.
17. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics. 2001;108:835-844.
18. Colmenares JP, Craig AS, Chu PS, et al. Emergency department evaluation of febrile children after the introduction of Prevnar. Tenn Med. 2005;98(4):184-186.
19. Gabriel ME, Aiuto L, Kohn N, et al. Management of febrile children in the conjugate pneumococcal vaccine era. Clin Pediatr (Phila). 2004;43(1):75-82.
20. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-897.
21. Pérez A, Sala P, Giménez M, et al. Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona. Eur J Clin Microbiol Infect Dis. 2004;23:677-681.
22. Belfer RA, Gittelman MA, Muniz AE. Management of febrile infants and children by pediatric emergency medicine and emergency medicine: comparison with practice guidelines. Pediatr Emerg Care. 2001;17(2):83-87.
23. Isaacman DJ, Kaminer K, Veligeti H, et al. Comparative practice patterns of emergency medicine physicians and pediatric emergency medicine physicians managing fever in young children. Pediatrics. 2001;108(2):354-358.